How Is Lung Cancer Operability Determined? (2026 Guide)

Whether lung cancer surgery is possible is decided by combining the stage (particularly whether there is mediastinal lymph node metastasis) with lung function and cardiac status. As a rule, stage 1–2 means surgery is the default approach, stage 3 calls for combination treatment, and stage 4 centers on systemic drug therapy.

Key Summary

• Operability is determined by three factors: stage, presence of mediastinal lymph node metastasis, and lung and cardiac function.
• In non-small cell lung cancer, stage 1–2 means the tumor is confined to the lung with no lymph node spread, or spread limited to lymph nodes near the lung — surgery is the default option here.
• Stage 3 involves mediastinal lymph node metastasis or invasion of nearby structures, so a multidisciplinary team jointly decides on a combination of surgery, chemotherapy, and radiation therapy.
• At stage 4 (metastasis to the opposite lung, brain, bone, or liver, or pleural effusion), surgery is not performed; systemic drug therapy becomes the central approach.
• Pulmonary function tests and cardiac evaluations confirm whether a patient can physically tolerate surgery — a judgment that varies by individual and is separate from the overall lung cancer 5-year relative survival rate of 42.5% (National Cancer Registry Statistics, 2019–2023).

What Are the Key Criteria That Determine Operability?

• The single most important factor is whether mediastinal lymph node metastasis is present. If there is no spread, or spread is limited to lymph nodes near the lung, surgery is considered first. If cancer has spread to the mediastinal lymph nodes or to distant organs such as the opposite lung, brain, bone, or liver, surgery is postponed or excluded from the treatment plan.
• Beyond staging, pulmonary function tests and cardiac evaluations confirm whether the patient can tolerate lobectomy and general anesthesia. Even with a favorable stage, insufficient lung function may lead the team to consider alternatives such as stereotactic radiation therapy (SBRT) instead of surgery.

In What Order Are the Tests Conducted?

• Direct answer: the sequence runs from tissue confirmation → staging → operability assessment → treatment decision.
• Step 1: A suspicious lesion is identified on chest CT, and tissue is obtained via bronchoscopy, CT-guided needle biopsy, or surgical biopsy depending on the lesion's location, to confirm whether it is non-small cell or small cell lung cancer and determine the histologic type.
• Step 2: PET-CT checks for lymph node and distant organ metastasis, while brain MRI checks for brain metastasis.
• Step 3: If mediastinal lymph node involvement is suspected, endobronchial ultrasound (EBUS) is used to directly sample the nodes and confirm metastasis.
• Step 4: If surgery is being considered, pulmonary function tests and cardiac evaluations assess whether the patient can tolerate the procedure.
• Step 5: For advanced or metastatic non-small cell lung cancer, genetic alterations such as EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, and NTRK, along with PD-L1 expression, are checked via NGS and other testing to jointly determine the direction of systemic therapy.

Does the Surgical Approach Differ by Stage?

• Direct answer: stage 1–2 typically uses thoracoscopic or robotic lobectomy as the default, and when the tumor is small and well-positioned, a more limited sublobar resection may be performed instead.
• Depending on surgical outcomes, adjuvant chemotherapy may be added, and if an EGFR mutation is present or PD-L1 criteria are met, postoperative targeted therapy or immunotherapy is now part of the standard approach.
• For stage 3 cases where surgery appears feasible, neoadjuvant chemotherapy and immunotherapy to shrink the tumor before surgery has become the established standard. If surgery is not feasible, concurrent chemoradiotherapy is given, followed by immunotherapy.
• For early-stage cancers where surgery is difficult due to age or lung function, stereotactic radiation therapy (SBRT) can complete treatment in just a few days.

FAQ — If I'm Told Surgery Isn't Possible, Does That Mean There's No Treatment Left?

No. Treatment options remain even when surgery is not feasible. For stage 3, concurrent chemoradiotherapy followed by immunotherapy is used. For stage 4, systemic drug therapy centered on targeted agents or immune checkpoint inhibitors is used. If there is brain or bone metastasis, additional targeted radiation therapy can be applied to those specific sites.

FAQ — Can Imaging and Test Results From My Home Country Be Used Directly for the Operability Assessment?

If you prepare chest CT, PET-CT, and brain MRI ideally as original DICOM files, along with pathology reports and genetic/biomarker test results (EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, NTRK, PD-L1, NGS), these can be used as reference for the operability assessment. If results are missing or incomplete, tissue slides or paraffin blocks can be sent for retesting, or testing can be performed after arrival.

Sources and Notes

• This article was written based on National Cancer Registry Statistics 2019–2023 (Korea Central Cancer Registry, National Cancer Center), SEER 2016–2022, and lung cancer information from the National Cancer Center.
• This content is intended for general medical information purposes only. Diagnosis, treatment methods, and outcomes may vary depending on individual circumstances. Accurate diagnosis and treatment decisions should always be made in consultation with a medical professional.